Quality of Life Considerations in Gynecologic Cancer

International Journal of Gynecology and Obstetrics

Volumn 95, Issue SUPPL. 1, 2006, Pages

  PENSON, Richard T ^a   WENZEL, Lari B ^b   VERGOTE, Ignace ^c   CELLA, David ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; GLUTAMINE; GOG 177; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IFOSFAMIDE; MESNA; PACLITAXEL; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDOXINE; VENLAFAXINE;

ABDOMINAL SURGERY; ALOPECIA; ANEMIA; ARTERY THROMBOSIS; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DIGESTIVE SYSTEM PERFORATION; EMOTIONAL STRESS; FATIGUE; FEAR; FEVER; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; GYNECOLOGIC CANCER; HAIR LOSS; HEALTH STATUS; HORMONAL THERAPY; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; HYPOXIA; INTESTINE OBSTRUCTION; LAPAROSCOPIC SURGERY; LAPAROSCOPY; LEUKOPENIA; MEASUREMENT; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVARY CANCER; PAIN; PALLIATIVE THERAPY; PATIENT CARE; PELVIS SURGERY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PULMONARY HYPERTENSION; QUALITY OF LIFE; SEXUAL INTERCOURSE; SEXUALITY; SIDE EFFECT; SOCIAL ASPECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION; WOUND HEALING IMPAIRMENT;

EID: 33845257555     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7292(06)60040-4     Document Type: Article

References (89)

1. Markman M. Unresolved issues in the chemotherapeutic management of gynecologic malignancies. Semin Oncol 33 2 Suppl. 6 (2006) S33-S38
2. Bottomley A. The cancer patient and quality of life. Oncologist 7 2 (2002) 120-125
3. Cella D. What do global quality-of-life questions really measure? Insights from Hobday et al and the "do something" rule. J Clin Oncol 21 16 (2003) 3178-9; author reply: 3179
4. Ferrell B., Smith S., Cullinane C., et al. Psychological well being and quality of life in ovarian cancer survivors. Cancer 98 5 (2003) 1061-1071
5. Kornblith A., Thaler H., Wong G., et al. Quality of life of women with ovarian cancer. Gynecol Oncol 59 2 (1995) 231-242
6. Gotay C., Korn E., McCabe M., et al. Quality-of-life assessment in cancer treatment protocols: research issues in protocol development. J Natl Cancer Inst 84 8 (1992) 575-579
7. Bodurka-Bevers D., Basen-Engquist K., Carmack C., et al. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol 78 3 Pt 1 (2000) 302-308
8. Calman K. Quality of life in cancer patients - an hypothesis. J Med Ethics 10 3 (1984) 124-127
9. Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL). Qual Life Res 2 2 (1993) 153-159
10. Aaronson N., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 5 (1993) 365-376
11. Cella D., Tulsky D., Gray G., et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11 3 (1993) 570-579
12. Basen-Engquist K., Bodurka-Bevers D., Fitzgerald M., et al. Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol 19 6 (2001) 1809-1817
13. Fish L., and Lewis L. Quality of life issues in the management of ovarian cancer. Semin Oncol 26 32 (1999) 9
14. Calhoun E., Welshman E., Chang C., et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13 6 (2003) 741-748
15. Greimel E., Bottomley A., Cull A., et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer 39 10 (2003) 1402-1408
16. Spitzer W., Dobson A., Hall J., et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chron Disease 34 (1981) 585-597
17. http://www.euroqol.org./
18. Wenzel L., Monk B., Huang H., et al. Clinically meaningful quality-of-life changes in ovarian cancer: Results from gynecologic oncology group clinical trial 152. Quality of life III: Translating the science of quality-of-life assessment into clinical practice, an example, driven approach for practicing clinicians and clinical researchers. Scottsdale, Arizona: Cinical Therapeutics: The International Peer. Reviewed Journal of Drug Therapy (2003)
19. Lederberg M., and Fitchett G. Can you measure a sunbeam with a ruler?. Psycho-oncology 8 (1999) 375-377
20. Levine M., and Ganz P. Beyond the development of quality-of-life instruments: where do we go from here?. J Clin Oncol 20 9 (2002) 2215-2216
21. Browman G. Science, language, intuition, and the many meanings of quality of life. J Clin Oncol 17 6 (1999) 1651-1653
22. Efficace F., Bottomley A., Osoba D., et al. Beyond the development of health-related quality-of-life (HRQOL) measures: A checklist for evaluating HRQOL outcomes in cancer clinical trials - does HRQOL evaluation in prostate cancer research inform clinical decision making?. J Clin Oncol 21 18 (2003) 3502-3511
23. Trimbos J., Maas C., Deruiter M., et al. A nerve-sparing radical hysterectomy: guidelines and feasibility in Western patients. Int J Gynecol Cancer 11 3 (2001) 180-186
24. Morris M. Management of stage IA cervical carcinoma. J Natl Cancer Inst Monogr 21 (1996) 47-52
25. Rose P. Type II radical hysterectomy: evaluating its role in cervical cancer. Gynecol Oncol 80 1 (2001) 1-2
26. Wenzel L., Dogan-Ates A., Habbal R., et al. Defining and measuring reproductive concerns of female cancer survivors. J Natl Cancer Inst Monogr 34 (2005) 94-98
27. Roy M., and Plante M. Radical vaginal trachelectomy for invasive cervical cancer. J Gynecol Obstet Biol Reprod (Paris) 29 3 (2000) 279-281
28. Pecorelli S., Odicino F., and Favalli G. Interval debulking surgery in advanced epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 16 4 (2002) 573-583
29. van der Burg M., van Lent M., Buyse M., et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332 10 (1995) 629-634
30. Rose P., Nerenstone S., Brady M., et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351 24 (2004) 2489-2497
31. Wenzel L., Huang H., Monk B., et al. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 23 24 (2005) 5605-5612
32. Crawford S., Vasey P., Paul J., et al. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol 23 34 (2005) 8802-8811
33. Caquant F., Mas-Calvet M., Turbelin C., et al. Endometrial cancer by laparoscopy and vaginal approach in the obese patient. Bull Cancer 93 4 (2006) 402-406
34. Walker J., Piedmonte M., Spirtos N., et al. Surgical staging of uterine cancer: Randomized phase III trial of laparoscopy vs laparotomy - A Gynecologic Oncology Group Study (GOG): Preliminary results. Journal of Clinical Oncology 24 18S (2006) 5010 (June 20 Supplement):
35. Kornblith K, Walker J, Huang H, et al. Quality of life (QOL) of patients in a randomized clinical trial of laparoscopy (scope) vs. open laparotomy (open) for the surgical resection and staging of uterine cancer: A Gynecologic Oncology Group (GOG) study. Gynecol Oncol; SGO Annual Meeting: 2006; Abs 47.
36. McGuire W., Hoskins W., Brady M., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334 1 (1996) 1-6
37. Armstrong D. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7 Suppl 5 (2002) 20-28
38. Ozols R., Bundy B., Greer B., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21 17 (2003) 3194-3200
39. Cella D., Paul D., Yount S., et al. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest 21 4 (2003) 526-535
40. Vasey P., Jayson G., Gordon A., et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96 22 (2004) 1682-1691
41. Parmar M., Ledermann J., Colombo N., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 9375 (2003) 2099-2106
42. Gralla R. Silk purse in Atlanta: a commentary on SWOG 9509, an advanced non-small cell lung cancer trial. Oncologist 4 3 (1999) 188-190
43. Pignata S., De Placido S., Biamonte R., et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer 6 (2006) 5
44. Dunton C. Management of treatment-related toxicity in advanced ovarian cancer. Oncologist 7 Suppl 5 (2002) 11-19
45. Seiden M. Ovarian cancer. Oncologist 6 4 (2001) 327-332
46. Hilpert F., Stahle A., Tome O., et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy - a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Ovarian Cancer Study Group. Support Care Cancer 13 10 (2005) 797-805
47. Lorusso D., Ferrandina G., Greggi S., et al. Phase III multicenter randomized trial of amifostine as cytoprotectaht in first-line chemotherapy in ovarian cancer patients. Ann Oncol 14 7 (2003) 1086-1093
48. Annas G. Informed consent, cancer, and truth in prognosis. N Engl J Med 330 3 (1994) 223-225
49. http://www.cochrane.org/
50. Armstrong D., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354 1 (2006) 34-43
51. Wenzel L., Huang H., Armstrong D., et al. Baseline quality of life (QOL) as a predictor of tolerance to intraperitoneal (IP) chemotherapy for advanced epithelial ovarian cancer (EOC): A Gynecologic Oncology Group (GOG) study. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 24 June 20 Supplement (2006) 5007
52. Markman M. Viewing ovarian cancer as a "chronic disease": what exactly does this mean?. Gynecol Oncol 100 2 (2006) 229-230
53. Markman M. Challenging ovarian cancer: how can we improve quantity and quality of life?. MedGenMed 4 4 (2002) 10
54. Fleming G., Brunette V., Cella D., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 22 11 (2004) 2159-2166
55. McQuellon R., Thaler H., Cella D., et al. Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 101 2 (2006) 296-304
56. Bookman MA, (GCIG) ftGCI. GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings; 2006; 24(June 20 Supplement):5002.
57. Burger RA, Sill M, J. Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. ASCO, 2005.
58. Garcia AA, Oza AM, Hirte H, et al. Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial. American Society of Clinical Oncology, 2006.
59. Cannistra S., Matulonis U., Penson R., et al. Bevacizumab (Avastin®) in patients with advanced platinum-resistant ovarian cancer. J Clin Oncol. Atlanta (2006)
60. Atkins M. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings; Vol 24: Plenary discussion, 2006.
61. Rose P., Bundy B., Watkins E., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340 15 (1999) 1144-1153
62. Stehman FB, Ali S, Gallup DG, et al. Radiation ±cisplatin for bulky stage IB cervical carcinoma; Long-term follow-up of a GOG trial. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2006;24(June 20 Supplement):5015.
63. Randall M., Filiaci V., Muss H., et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 24 1 (2006) 36-44
64. Watkins-Bruner D., Barsevick A., Tian C., et al. Quality of life trade-off to incremental gain in survival on Gynecologic Oncology Group (GOG) Protocol 122: Whole abdominal irradiation (WAI) vs. doxorubicin-platinum (AP) chemotherapy in advanced endometrial cancer. Proc Am Soc Clin Oncol 22 (2003) 1803
65. Wolfson AH, Brady MF, Rocereto TF, et al. A Gynecologic Oncology Group randomized trial of whole abdominal irradiation (WAI) vs cisplatin-ifosfamide+mesna (CIM) in optimally debulked stage I-IV carcinosarcoma (CS) of the uterus. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2006;24(June 20 Supplement):5001.
66. Steginga S., and Dunn J. Women's experiences following treatment for gynecologic cancer. Oncol Nurs Forum 24 8 (1997) 1403-1408
67. Carelle N., Piotto E., Bellanger A., et al. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95 1 (2002) 155-163
68. Wenzel L., Donnelly J., Fowler J., et al. Resilience, Reflection, and Residual Stress in Ovarian Cancer Survivorship: A Gynecologic Oncology Group Study. Psycho-Oncology 11 2 (2002) 142-154
69. Wenzel L., Glanz K., and Lerman C. Stress, coping and health behavior. In: Glanz K., Rimer B., and Lewis F. (Eds). Health behavior and health education (2002), Theory, research and practice Jossey-Bass Inc.
70. Donnelly J., Kornblith A., Fleishman S., et al. A pilot study of interpersonal psychotherapy by telephone with cancer patients and their partners. Psychooncology 9 1 (2000) 44-56
71. Andersen B., Farrar W., Golden-Kreutz D., et al. Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial. J Clin Oncol 22 17 (2004) 3570-3580
72. Sheard T., and Maguire P. The effect of psychological interventions on anxiety and depression in cancer patients: results of two metaanalyses. Br J Cancer 80 11 (1999) 1770-1780
73. Le T., Leis A., Pahwa P., et al. Quality-of-life issues in patients with ovarian cancer and their caregivers: a review. Obstet Gynecol Surv 58 11 (2003) 749-758
74. Le T., Leis A., Pahwa P., et al. Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment. Gynecol Oncol 92 3 (2004) 839-844
75. Le T., Leis A., Pahwa P., et al. Quality of life evaluations of caregivers of ovarian cancer patients during chemotherapy treatment. J Obstet Gynaecol Can 26 7 (2004) 627-631
76. Hipkins J., Whitworth M., Tarrier N., and Jayson G. Social support, anxiety and depression after chemotherapy for ovarian cancer: a prospective study. Br J Health Psychol 9 Pt 4 (2004) 569-581
77. Markman M. Management of ovarian cancer. An impressive history of improvement in survival and quality of life. Oncology (Williston Park) 20 4 (2006) 347-354 discussion 354, 357-8, 364 passim
78. Gelber R., Goldhirsch A., and Cavalli F. Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group. Ann Intern Med 114 8 (1911) 621-628
79. Doyle C., Crump M., Pintilie M., et al. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 19 5 (2001) 1266-1274
80. Pignata S., Ballatori E., Favalli G., et al. Quality of life: gynaecological cancers. Ann Oncol 12 Suppl 3 (2001) S37-S42
81. Duffy M. Recent surgical approaches to gynecologic oncology. Nurs Clin North Am 36 3 (2001) 603-15, XII
82. Brassil D., and Keller M. Female sexual dysfunction: definitions, causes, and treatment. Urol Nurs 22 4 (2002) 237-44, 284; quiz 245, 248
83. Wilmoth M., and Spinelli A. Sexual implications of gynecologic cancer treatments. J Obstet Gynecol Neonatal Nurs 29 4 (2000) 413-421
84. Denton A., and Maher E. Interventions for the physical aspects of sexual dysfunction in women following pelvic radiotherapy. Cochrane Database Syst Rev 1 (2003) CD003750
85. Andersen B. Sexual functioning morbidity among cancer survivors. Current status and future research directions. Cancer 55 8 (1985) 1835-1842
86. Phillips N. Female sexual dysfunction: evaluation and treatment. Am Fam Physician 62 1 (2000) 127-136 141-2
87. Werizel L., Berkowitz R., Robinson S., et al. The psychological, social, and sexual consequences of gestational trophoblastic disease. Gynecol Oncol 46 1 (1992) 74-81
88. Swenson M., MacLeod J., Williams S., et al. Quality of life after among ovarian germ cell cancer survivors: a narrative analysis. Oncol Nurs Forum 30 3 (2003) 380
89. Williams S., Miller A., Cella D., et al. Relationship Issues and Sexual Functioning in Ovarian Germ Cell Cancer Survivors. Proc Am Soc Clin Oncol (2001)